/
Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Unless otherwise noted, all references in this document to a particular year refer to the Company s fiscal year.
Operating margin is thin at 1.54%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 12.4%, still solid.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$403.43B
▲ +12.4% YoY
Net Income (TTM)
$4.76B
▲ +44.5% YoY
Op. Margin
1.54%
▲ +0.3pp YoY
ROIC
54.23%
▲ +11.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$5.72B
▲ +3.1% YoY
Op. Cash Flow (TTM)
$6.16B
▲ +1.2% YoY
Net Debt
$6.09B
Cash & Equiv.
$3.98B
5Y CAGR: +11.1%
5Y CAGR: +6.9%
Continue Research